InvestorsHub Logo

Waitforit53

11/25/14 8:26 AM

#26150 RE: Tinh2p #26144

I think so Tin. This should be the cheapest clinical while yielding some of the most important data in decades of cancer research. My favor quote from Punit's blogg,

This powerful combination is expected to treat the larger population of approximately 70% of the patients for which it is not currently effective by one of the most exciting breakthrough drugs in treatment of cancer.



There is A LOT on the line here. This is where Oncosec gets to find out if they actually can reach that 70%, and if they can---it's full steam ahead in all other cancer indications with Merck.